ArticleMedical oncology (Northwood, London, England)2023
Anticancer activity of lycopene in HT-29 colon cancer cell line.
Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Potential Use of Tomato Peel, a Rich Source of Lycopene, for Cancer Treatment.Molecules (Basel, Switzerland) · 2024Pooled it
- Cubosomal nanoparticles of lycopene as a novel platform for enhancement in antioxidant and anticancer properties with a molecular docking study.Scientific reports · 2026Article
- Chemopreventive Effects of Lycopene in miR-21 Knockout and Wild-Type Pancreatic Cancer Cells.Scientifica · 2026Article
- Antioxidant, Antidiabetic, Anti-Obesity, and Anti-Inflammatory Activity of Tomato-Based Functional Snack Bars Enriched with Pea and RuBisCO Proteins.Foods (Basel, Switzerland) · 2025Article
- Astaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy.Food science & nutrition · 2025Review
- Incredible use of plant-derived bioactives as anticancer agents.RSC advances · 2025Review
- HER-2 SMASH.Cancer chemotherapy and pharmacology · 2024Article
- Secondary Metabolites ofJournal of fungi (Basel, Switzerland) · 2024Review
- A new methodology to reveal potential nucleic acid modifications associated with the risk of endometrial cancer through dispersive solid-phase extraction coupled with UHPLC-QE-Orbitrap-MS/MS and HPLC-UV.Analytical and bioanalytical chemistry · 2024Article
- Physicochemical properties, mechanism of action of lycopene and its application in poultry and ruminant production.Frontiers in veterinary science · 2024Review
- Lycopene: A Potent Antioxidant with Multiple Health Benefits.Journal of nutrition and metabolism · 2024Review
- Recent Advances in Lycopene for Food Preservation and Shelf-Life Extension.Foods (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An inverse association between serum lycopene levels and the risk of cancers has been pointed out by many prospective and retrospective epidemiological studies which prompted more studies to be performed on animal models and cell cultures in order to test this hypothesis. The aim of the present study was to evaluate the antiproliferative and pro-apoptotic effect of lycopene on colon cancer HT-29 cell line. The effect of lycopene on the viability of HT-29 cell line was investigated using XTT assay. The levels of Bcl-2, cleaved caspase 3, BAX, cleaved PARP, and 8-oxo-dG in lycopene-treated HT-29 cells were measured using ELISA. Gamma-H2AX and cytochrome c expression was assessed semi-quantitatively using immunofluorescence staining. Lycopene at doses of 10 and 20 μM produced a significant antiproliferative effect on HT-29 cells compared to the control (p < 0.05). The IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.